Synexus

Synexus expands presence in South Africa

Wednesday, July 18, 2012 01:21 PM

Synexus has further expanded its global presence with the opening of a new in-patient facility in Pretoria, South Africa. Synexus now has a total of four sites in South Africa, which provide access to millions of patients.

More... »

Synexus aquires Osteomed of Poland

Wednesday, May 2, 2012 04:59 PM

Synexus, a global company that recruits and runs late phase clinical trials, has further strengthened its leadership position in Poland with the acquisition of Warsaw-based Osteomed for an undisclosed sum.

More... »

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

Synexus names Pilgrim chairman

Monday, October 17, 2011 01:01 PM

Alan Pilgrim has taken over as chairman of Synexus from Trevor Jones, who continues on the board as a director and becomes president of the Synexus’ Scientific advisory board.

More... »

Large SMOs Synexus and Radiant head to India seeking large pool of treatment-naïve patients

Monday, January 24, 2011 12:02 PM

Two large site management organizations (SMOs), Radiant Research and Synexus, are planning expansions into India.

More... »

Synexus sees clinical trials rise 25% in Hungary

Tuesday, August 24, 2010 07:00 AM

Synexus’ clinical trials activity in Hungary increased by 25% during the first half of 2010. The company’s Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company’s most successful CEE sites. The Budapest-based operation has been involved in more than 74 trials since being acquired by Synexus, and has randomized over 600 patients. Dr Erika Nemeth, Synexus’ country manager in Hungary, said the trend of more clinical trials being conducted in Hungary is set to continue: “The high standards of medical and research & development expertise in Hungary has resulted in high levels of participation in clinical trials and means that pharma and biotech companies remain keen to include Hungary as part of their global clinical trial programs.” The prevalence of chronic conditions including CVD and COPD among the Hungarian population, together with little preventative healthcare and healthcare education, means the treatment naïve population remains substantial and therefore attractive for clinical trials. Also, the pharmaceutical market in Hungary is set to increase significantly in the coming decade, encouraging the major players to establish a stronger and more proactive presence there before their new drugs come to market. Synexus CEO Michael Fort said the productivity of investigators, the attractive overhead costs and the world-renowned medical expertise and innovation in Hungary make it one of his company’s key areas for future development.

More... »

Synexus Expands Operations in Poland

Wednesday, July 7, 2010 08:45 AM

Synexus, an international recruiter and operator of clinical trials, is expanding its operations in Gdynia, Poland. It has also recently increased the capacity of its original center in Wroclaw. The new dedicated research center in Gdynia will have the capacity for four full-time investigators and will include a wide range of diagnostic instruments to cover Synexus’ expanding therapy area coverage. Dr. Radoslaw Janiak, Synexus Country Manager for Poland, said, “Being part of Synexus’ worldwide operations means that we are increasingly involved in large global clinical trials. We are able to recruit the right numbers of patients within the right time frame, and that’s exactly what sponsors are looking for. We are seeing considerable interest from a number of leading Pharmas and CROs who are keen on the developments we have under way to increase our capacity here.” Manchester, England-based Synexus has been operating in Poland since 2006 and expanded its operations there in 2009 when it acquired three new dedicated research centers in Warsaw, Gdynia and Katowice, following its takeover of CLCC.

More... »

Sarah Cannon Names New CFO

Friday, March 19, 2010 07:05 AM

Strategic research organization Sarah Cannon Research Institute (SCRI) appointed Dean Ferrigno as chief financial officer (CFO), replacing Phil Cestaro, who is now president, SCRI Services. SCRI Services specializes in clinical trial administration with a focus on oncology drug development programs. Cestaro, who joined the company in 2006, will continue to be SCRI’s chief information officer in addition to the new position.

More... »

Synexus Acquisition of ClinPharm to Be Biggest Deal in Company History

Monday, December 7, 2009 08:52 PM

Synexus is acquiring Leipzig, Germany-based ClinPharm in the company’s largest deal ever.

More... »

Synexus Acquires Three Sites in Poland

Monday, August 31, 2009 10:23 AM

Manchester, England-based Synexus plans to double its operations in Poland through the acquisition of three clinical trial sites.

More... »